^
Association details:
| Biomarker: | Chr del(11)(q22.3) |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Calquence (acalabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
Published date:
04/09/2020
Excerpt:
In this phase 1b/2 study, 134 patients with relapsed/refractory CLL or SLL (median age, 66 years [range, 42-85 years]; median prior therapies, 2 [range, 1-13]) received acalabrutinib...responses were similar regardless of genomic features (presence of del(11)(q22.3), del(17)(p13.1), complex karyotype, or immunoglobulin variable region heavy chain mutation status).
DOI:
10.1182/blood.2018884940
Trial ID:
